Caudill Cortney's Form 4 filing
Halozyme Therapeutics, Inc. (HALO) · filed Dec 19, 2025
- Accession no.
- 0001159036-25-000075
- Filed
- Dec 19, 2025
- Trade date
- Nov 1, 2025
- Filing delay
- 48 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $277.9K. It was filed 48 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Caudill CortneyCIK 0002090209 | Officer (SVP, CHIEF OPERATING OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 1, 2025 | Common Stock | MOption exerciseAcquired | +9,326 | $0.00 | $0 | 17,000 | Direct | |
| Nov 1, 2025 | Common Stock | SSaleDisposed | −4,263 | $65.19 | −$277,904.97 | 12,737 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 1, 2025 | Common Stock | MOption exerciseDisposed | −9,326 | $0.00 | $0 | 18,651 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.